April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Study of Inotuzumab Ozogamicin Halted After Interim Analysis
May 22nd 2013A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.
Read More
Potential Therapeutic Target Identified in Acute Myeloid Leukemia
May 17th 2013Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.
Read More
Quizartinib Sparks Remission in Some Patients With Resistant AML
December 18th 2012Quizartinib, a novel tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia in results of a phase II study presented during the 54th Annual ASH Meeting.
Read More
Ibrutinib Performance in CLL Patients Hailed
December 13th 2012The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab, raising the prospect of a promising new therapy for elderly and frail patients who currently have few viable options.
Read More
Pomalidomide Labeled an Advance in Multiple Myeloma
December 9th 2012The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Read More
Ponatinib Stimulates ‘Powerful’ Response in Treatment-Resistant Leukemias
December 8th 2012Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance—including the stubborn T315I mutation—in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More